We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to... FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for treating wound healing. Its early-stage research programs include CYTER915 which is designed to regenerate or reinvigorate production of the thymus and/or spleen; and TCB190 for the treatment of cancers. The company was incorporated in 2021 and is based in Houston, Texas. FibroBiologics, Inc. operates as a subsidiary of Spinalcyte Llc. Show more
HOUSTON, April 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a highly respected, global provider of drug...
HOUSTON, April 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on...
HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the...
HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment PR Newswire HOUSTON, March 19, 2024 HOUSTON, March 19, 2024 /PRNewswire/ -- FibroBiologics, Inc...
FibroBiologics to Present at Advanced Wound Care Summit USA PR Newswire HOUSTON, March 13, 2024 HOUSTON, March 13, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a...
FibroBiologics Appoints Ruben A. Garcia as General Counsel PR Newswire HOUSTON, March 6, 2024 HOUSTON, March 6, 2024 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a...
FibroBiologics Files 2023 Form 10-K Annual Report PR Newswire HOUSTON, Feb. 29, 2024 HOUSTON, Feb. 29, 2024 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics") a clinical-stage...
FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum PR Newswire HOUSTON, Feb. 20, 2024 HOUSTON...
FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases PR Newswire HOUSTON, Feb. 13, 2024 HOUSTON, Feb. 13, 2024 /PRNewswire/...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1 | -9.00090009001 | 11.11 | 11.7 | 9.61 | 43293 | 11.11481367 | CS |
| 4 | -0.72 | -6.64819944598 | 10.83 | 11.88 | 9.185 | 68917 | 10.86106846 | CS |
| 12 | -3.62 | -26.365622724 | 13.73 | 19.6 | 6.53 | 95434 | 12.17509691 | CS |
| 26 | -19.89 | -66.3 | 30 | 55 | 6.53 | 97761 | 12.55339561 | CS |
| 52 | -19.89 | -66.3 | 30 | 55 | 6.53 | 97761 | 12.55339561 | CS |
| 156 | -19.89 | -66.3 | 30 | 55 | 6.53 | 97761 | 12.55339561 | CS |
| 260 | -19.89 | -66.3 | 30 | 55 | 6.53 | 97761 | 12.55339561 | CS |
enthalpy
2 months ago
Monksdream
2 months ago
Invest-in-America
2 months ago
GhosTraderX
2 months ago
TheFinalCD
2 months ago
Monksdream
3 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
